Nantahala Capital Management’s Zevra Therapeutics ZVRA Stock Holding History

Nantahala Capital Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$23.5M	Buy	2,521,936 +750,000	+42%	+$6.76M	0.87%	29
2025 Q4	$15.9M	Sell	1,771,936 -200,000	-10%	-$1.89M	0.52%	46
2025 Q3	$18.8M	Buy	1,971,936 +500,000	+34%	+$5.01M	0.65%	36
2025 Q2	$13M	Hold	1,471,936	–	–	0.51%	44
2025 Q1	$11M	Sell	1,471,936 -868,397	-37%	-$6.9M	0.44%	38
2024 Q4	$19.5M	Sell	2,340,333 -583,688	-20%	-$4.98M	0.84%	25
2024 Q3	$20.3M	Buy	2,924,021 +504,586	+21%	+$3.42M	1.03%	22
2024 Q2	$11.9M	Sell	2,419,435 -33,970	-1%	-$161K	0.69%	28
2024 Q1	$14.2M	Hold	2,453,405	–	–	0.81%	29
2023 Q4	$16.1M	Buy	2,453,405 +145,189	+6%	+$679K	0.96%	19
2023 Q3	$11.1M	Buy	+2,308,216	New	+$11.5M	0.95%	22

Other funds holding ZVRA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Nantahala Capital Management's ZVRA Position: Q1 2026 in Review

Nantahala Capital Management increased its Zevra Therapeutics (ZVRA) stake by 42% in Q1 2026, buying an estimated $6.76M and bringing the position to 2,521,936 shares worth $23.5M. The position accounts for 0.87% of the portfolio, ranked #29.

Nantahala Capital Management first reported a position in ZVRA in Q3 2023 and has held it in 11 quarters since. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

Nantahala Capital Management held 2,521,936 shares of Zevra Therapeutics worth $23.5M as of Q1 2026.
Nantahala Capital Management bought 750,000 Zevra Therapeutics shares in Q1 2026, an estimated $6.76M.
Zevra Therapeutics made up 0.87% of Nantahala Capital Management's portfolio in Q1 2026, its #29 holding.
Nantahala Capital Management first reported a position in Zevra Therapeutics in Q3 2023 and has held it in 11 quarters since.
148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on Nantahala Capital Management's 13F filing for Q1 2026, filed 15 May 2026.